V Wealth Management LLC Takes Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

V Wealth Management LLC acquired a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the second quarter, Holdings Channel reports. The fund acquired 16,576 shares of the biotechnology company’s stock, valued at approximately $313,000.

Other institutional investors also recently added to or reduced their stakes in the company. Swiss National Bank boosted its position in Ironwood Pharmaceuticals by 1.2% in the first quarter. Swiss National Bank now owns 205,300 shares of the biotechnology company’s stock worth $3,502,000 after buying an additional 2,400 shares during the period. Pictet Asset Management Ltd. boosted its position in Ironwood Pharmaceuticals by 68.3% in the first quarter. Pictet Asset Management Ltd. now owns 1,631,192 shares of the biotechnology company’s stock worth $27,828,000 after buying an additional 661,868 shares during the period. American Century Companies Inc. bought a new position in Ironwood Pharmaceuticals during the first quarter worth about $1,879,000. Strs Ohio boosted its position in Ironwood Pharmaceuticals by 132.1% in the first quarter. Strs Ohio now owns 6,500 shares of the biotechnology company’s stock worth $110,000 after buying an additional 3,700 shares during the period. Finally, Nationwide Fund Advisors boosted its position in Ironwood Pharmaceuticals by 108.5% in the first quarter. Nationwide Fund Advisors now owns 229,682 shares of the biotechnology company’s stock worth $3,918,000 after buying an additional 119,509 shares during the period. 97.36% of the stock is currently owned by institutional investors.

Ironwood Pharmaceuticals, Inc. (IRWD) traded down 0.37% during trading on Monday, hitting $18.99. 337,172 shares of the company’s stock traded hands. The company’s 50 day moving average is $18.20 and its 200-day moving average is $16.70. Ironwood Pharmaceuticals, Inc. has a 12 month low of $12.48 and a 12 month high of $19.94. The stock’s market cap is $2.82 billion.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Monday, May 8th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.14. The firm had revenue of $52.16 million during the quarter, compared to the consensus estimate of $69.39 million. Ironwood Pharmaceuticals had a negative return on equity of 195.06% and a negative net margin of 46.49%. The company’s quarterly revenue was down 21.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.08) EPS. On average, analysts predict that Ironwood Pharmaceuticals, Inc. will post ($0.91) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “V Wealth Management LLC Takes Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/2723488/v-wealth-management-llc-takes-position-in-ironwood-pharmaceuticals-inc-nasdaqirwd.html.

A number of research firms have recently issued reports on IRWD. BidaskClub raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Zacks Investment Research raised shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday. Mizuho raised their price target on shares of Ironwood Pharmaceuticals from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, July 4th. ValuEngine raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Wedbush reaffirmed a “neutral” rating and issued a $13.00 price target on shares of Ironwood Pharmaceuticals in a research report on Friday, June 16th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Ironwood Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $18.20.

In other news, insider Thomas A. Mccourt sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $18.20, for a total value of $546,000.00. Following the transaction, the insider now owns 30,000 shares in the company, valued at $546,000. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Halley E. Gilbert sold 35,000 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $19.75, for a total transaction of $691,250.00. Following the completion of the transaction, the insider now owns 35,000 shares in the company, valued at approximately $691,250. The disclosure for this sale can be found here. Corporate insiders own 7.63% of the company’s stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.